SubsidieMeestersThe first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika
ATLAS aims to develop the first broad-spectrum antiviral for flavivirus infections, conducting Phase I and IIa trials for dengue to attract pharmaceutical partnerships for commercialization.
Projectdetails
Introduction
WHO, governments, and health institutes are urgently seeking methods to prevent future catastrophic flavivirus outbreaks affecting millions. Annually, over 40% of the global population is at risk, resulting in approximately 395 million infections, more than 25,000 deaths (mainly children), 750,000 disability-adjusted life years, and over €9 billion in direct and indirect costs.
Project Overview
As there are no effective treatments or vaccines available, ATLAS will provide a breakthrough in broad-spectrum antivirals: the first-in-class drug to combat the global health emergency of flaviviral infections.
Objectives
In the ATLAS project, Protinhi will:
- Finalize clinical trial-enabling studies and pharmaceutical development.
- Obtain proof-of-concept in humans by conducting Phase I and Phase IIa clinical trials against the most common flavivirus: dengue.
Strategic Partnerships
This will put the company in an excellent position to attract interest from pharmaceutical companies (e.g., Gilead, J&J, MSD) for a strategic partnership for late clinical development and commercialization.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 14.465.988 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 31-8-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PROTINHI BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Universal building blocks for antigen presentation to uncover the flavivirus-directed antibody responseThe FLAVIR project aims to develop a structural proteomics toolkit using mass spectrometry and electron microscopy to enhance understanding of neutralizing antibody responses against flaviviruses for vaccine development. | ERC STG | € 1.687.500 | 2023 | Details |
Mobile Bio-Lab to support first response in Arbovirus outbreaksMOBVEC aims to develop the first VBD Mobile Bio-Lab to provide real-time vector surveillance and disease modeling, enhancing outbreak response and saving lives and healthcare costs. | EIC Pathfinder | € 2.998.500 | 2023 | Details |
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitorsThis project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets. | ERC POC | € 150.000 | 2022 | Details |
Broad-spectrum Antiviral siRNAs: Influenza Strains Targeted by AnticipationThe BARISTA project aims to develop a novel antiviral therapy for future influenza strains using optimized siRNA guided by NMR analysis, enhancing preparedness against emerging viruses. | ERC POC | € 150.000 | 2025 | Details |
Universal building blocks for antigen presentation to uncover the flavivirus-directed antibody response
The FLAVIR project aims to develop a structural proteomics toolkit using mass spectrometry and electron microscopy to enhance understanding of neutralizing antibody responses against flaviviruses for vaccine development.
Mobile Bio-Lab to support first response in Arbovirus outbreaks
MOBVEC aims to develop the first VBD Mobile Bio-Lab to provide real-time vector surveillance and disease modeling, enhancing outbreak response and saving lives and healthcare costs.
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitors
This project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets.
Broad-spectrum Antiviral siRNAs: Influenza Strains Targeted by Anticipation
The BARISTA project aims to develop a novel antiviral therapy for future influenza strains using optimized siRNA guided by NMR analysis, enhancing preparedness against emerging viruses.